We used two different capture sets in this analysis; first, a capture set consisting of CRC-specific targets (capture set of genes mutated in CRC); second, a capture set consisting of Pold1 and Pole (capture set of polymerase genes, pol DE capture set). Probes for these capture sets were ordered from IDT, and sequences are provided in Dataset S1.
Explanation and Discussion of Modeling
In the subsequent sections, the following topics are considered: (1) presentation of the mathematical approach, (2) application of the approach to human colon cancers sequenced at multiple depths, (3) Methods for estimating mutation frequencies for tumor masses large enough to be clinically diagnosable (4) comparison to the related mathematical approaches of Williams et al 5 and of Bozic et al 6, 7 (5) discussion of assumptions and approximations of the model , (6) illustration of the dependence of actual mutation frequency on the growth pattern, and evaluation of the likely consequences for the estimate of tumor mutational burden and for the mutator hypothesis, (7) discussion of the likelihood of existing resistance to one or multiple non-cross resistant agents in malignant cells during tumor growth, and simulations of the sensitivity of this method for detecting weak selection.
Mathematical approach.
In order to model the fraction of apparently unmutated single base loci, we integrate over the entire history of the tumor, determine the fraction of apparently unmutated single base loci for daughter cells born at different times, and obtain the average fraction of apparently unmutated single base loci, weighted by the number of daughter cells born at different times. For mutations detected at a given duplex sequencing depth, the fraction of apparently unmutated single base loci is constant (independent of n(t)), making the average simple to calculate. At early timepoints, when there are few cells, it is less likely that a mutation will arise because there are fewer cells dividing at that time. But, if a mutation arises at this early time, it will be present in a larger fraction of the cells in the final tumor, because it is closer to the trunk of the evolutionary tree, and therefore will be more likely to be detectable. These two factors (the lower likelihood of a mutation at earlier times but greater likelihood of detecting a mutation which does occur at an earlier time) exactly counterbalance each other to give a constant number of expected detectable mutations arising at any time. Specifically, at any given time t, we have (# symbolizes "number"): # ℎ ℎ = ;<=-?@@ ( ) (Equation S1)
In equation (S1), we assume that the n(t) cells present at time t undergo effective and synchronous divisions, eventually creating a new cell generation of n(t) daughter cells. This may require more than n(t) actual cell divisions. Note that expectation values need not be integers, and unlike probabilities, are not restricted to values, between zero and one.
In equation S2, we consider the branching nature of tumor evolution, and the fact that cells born in a larger tumor are further out on branches.
follows from equation S2, and the fact that we are randomly sampling the sequences of cells from the tumor at depth D.
Multiplying equation S1 by equation S3, we find:
gives the average for the expected number of mutations detected at a single base arising at time t. The question of the distribution around the average is an interesting one. Although our model has some similarities with the Luria-Delbrὓck 8 experiment, our experimental conditions differ slightly and allow us to utilize the zero term of the Poisson distribution rather than the Luria-Delbrὓck distribution, as discussed in the main text. Briefly, as discussed in Luria-Delbrὓck, this approximation is accurate if the number of observations is larger than the reciprocal of the mutation rate, which was not true in their experiment, but is true in ours. We have further checked the variance/mean ratio of the experimental data corresponding to equation S4 and found that it is close to one, characteristic of the Poisson but not of the Luria-Delbrὓck.
From equation S4 and the zero term of the Poisson distribution, it follows that the fraction of apparently unmutated single base loci Fapparent-unmutated from mutations arising in cells born at any time t is given by: Since (S5) is independent of time, a weighted average over the history of the tumor is given by the same expression. When we take the population-weighted average of equation S5, we integrate over all times in the tumor's history. Since every cell in the tumor was born at some point in the tumor's history, this integral over time is equivalent to integrating over all cells in the tumor. The average is then the time integral of (S5) over 0 to T, divided by T:
GHHGI?J=F<J;<=G=?K = F L MNOPQRR S (Equation S6)
Method for estimating kmut-eff from sequencing at multiple duplex depths.
Taking the natural logarithm of both sides of (S6), we obtain:
ln W GHHGI?J=F<J;<=G=?K X = − ;<=F?@@ (Equation S7) Thus, plotting the natural logarithm of the fraction of apparently mutated single base loci for several different duplex sequencing depths should yield a straight line with slope -kmut-eff. At duplex depth (D) = 0, no mutations will be observed and the fraction of apparently unmutated single base loci will be 1, leading to a natural logarithm of 0. Thus, the origin (0, 0) should also be on the line.
Fraction of unmutated single base loci in every cell in the tumor.
If we could sequence every single cell in the tumor, we would determine the actual value of this quantity. Thus, this number is given by equation S6, when D = N:
Application to 5 tumors sequenced at multiple depths. The analysis above predicts that a plot of ln(Fapparent-unmutated) vs D will be linear, with a negative slope equal to -kmut-eff, and will go through the origin although this point was not entered into the regression (all sites apparently unmutated at a sequencing depth of zero).
We find this is indeed the case for the mismatch repair proficient colorectal cancers that were sequenced at 4 depths ranging up to 20,000 (Figures S1a-e, Table S3 ) ). Linear correlation coefficients R 2 ranged from 0.953 to 0.999, with a mean +/-1 standard error of 0.974 +/-0.017. The percent of variation in data explained by the linear model is given by 100 times the square of the correlation coefficient, and ranged from a low of 90.8% in one tumor to a high of 99.9%, with a mean +/-1 standard error of 94.9 +/-3.3 %.
Only one of 5 estimated y-intercepts is statistically different from zero according to a 2-sided 95% confidence interval using the student's t-test with 2 degrees of freedom, and, for that one, the lower boundary of its 95% confidence interval was approximately 15% of the smallest data-point value. The mean+/-one standard error of the estimated y intercepts over the 5 tumors is -4.3 +/-5.5 X 10 -4 , indicating that the overall estimate of the y intercept is less than one standard deviation from zero. The excellent agreement of data with the model using five separate tumors renders more complex models less likely.
The estimated effective mutation rates kmut-eff for the 5 tumors ranges from 2.8 X 10 -7 to 1.5 X 10 -6 . The mean effective mutation rate (+/-1 standard error) over 5 tumors is 7.1 +/-4.4 X 10 -7 per base per effective cell division. For a genome of 3.1 X 10 9 bases, this means that each surviving new cell that adds to the tumor population has approximately 2,200 new mutations compared to its parent. Since these mutations are occurring randomly throughout the genome, only 1% of which is coding, this amounts to approximately 22 new mutations in coding segments per daughter cell, some of which will be synonymous. Many of these mutations will be private and only detectable if sequencing to single cell depth.
Relationship to earlier work 5-7,9-14 .
There have been many attempts to model tumor progression. Beckman and Loeb 11 Herein, we compare and contrast the proposed models and methods.
The Williams et al. 5 modelling approach and ours are similar in a number of important respects:
• Both use quantitative analysis of rare mutations to support the theory of neutral evolution.
• Both parameterize the model in terms of observables such as effective cell divisions, rather than on parameters such as actual cell divisions, that are difficult to infer. • Both predict a linear relationship between sequencing depth and a quantity related to observed genetic diversity, wherein the slope reveals the effective mutation rate, i.e. kmut-eff. • For all observations at depths of order of magnitude less than the reciprocal of the mutation rate, (in our case less than the order of 1.4 X 10 6 ), the predictions of the two approaches are identical. A mathematical explanation of why this is the case is given at the end of this section. • Both models conclude that significant subclonal diversity might be a source of pre-existing drug resistance.
Our approach and that of Williams et al. 5 approach differ in several important respects:
• Purpose: Williams et al. 5 examined the TCGA database at low depth utilizing a variety of techniques with varying accuracy, and described the statistical distribution of mutation frequencies in whole exome sequencing within tumor types. The TCGA database scores primarily for clonal mutations. In contrast, we isolated DNA from surgical specimens and used an assay that is 10,000-fold more accurate than standard NGS to examine rare subclonal mutations at depths of up to 20,000X. • Representation of distribution of variants as a function of their frequency: Williams et al. 5 implicitly assume that any new mutation occurring at time t is occurring in only one copy, rather than being born new in multiple copies in different cells: "for a new mutation occurring at any time t, its allelic frequency (relative fraction) f must be the inverse of the number of alleles in the population." This quote drives equation (5) in the Williams et al. 5 paper and the rest of the analysis. This assumption, that any new mutation at a particular site occurs uniquely, rather than simultaneously in multiple cells, is termed the "infinite sites approximation." 13 The assertion is valid for depths less than one over the mutation rate, i.e. the subject of the Williams et al. 5 analysis and our experimental work. In contrast, our equation (S1) describes the expected number of new mutations simultaneously within different cells as the product of a mutation rate and the number of cells dividing simultaneously. This is an average and does not have to be an integer like 0 or 1. The probability that there will be any given integral number of DNA molecules with the variant of interest is then given by the Poisson distribution. Below, we will derive the predictions of the mutant allele frequency as a function of the number of alleles in the population for our model, which does not rely on the infinite sites approximation, and contrast it with other models. • Difference between the methods' predictions at depths less than one over the mutation rate, i.e. variant frequencies greater than the mutation rate: in this range, the two methods give very similar predictions. This is because at these depths, it is unlikely that there will be more than one copy of a given new mutation being formed at any instant. When kmut-eff n(t) << 1, most sites in the genome will remain unmutated, and a small minority of sites will have only one copy of a new mutation formed at that instant. A very small minority of sites will have 2 or more copies of the new mutation simultaneously forming, and thus the Williams et al. 5 approximation is accurate in this range ( Figure 5 , main text). • Difference between the methods' predictions at depths much larger than one over the mutation rate: in this range, the Williams et al. 5 approach, which asserts that the variant frequency will be inversely proportional to the depth at all depths, differs from ours. Given the mutation rate of approximately 7 X 10 -7 per effective cell division, and the fact that the smallest tumor visible on CT will contain between 10 8 and 10 9 cells 15 , the product kmut-eff times n(t) will be >> 1 before the tumor is diagnosed and this will only increase as the tumor grows. In such cases, we do not believe that the variant frequency will be 1/n(t) (or 1/D, given that at depth D we are on average observing mutations that occurred when n(t) =D) as asserted by Williams et al. 5 . Rather the expected number of copies of a new mutation formed at a doubling from n(t) to 2n(t) will be as given in equation (S1), i.e. kmut-eff n(t). For the case of the tumor with 10 9 cells, if they all divide approximately simultaneously, we expect approximately (7 X 10 -7 ) X 10 9 or 700 of the newly formed 10 9 daughter cells to contain the same new variant created approximately simultaneously.
The chance of only one copy of the new variant being created under these circumstances is negligible. Thus, at high n(t), the variant frequency does not continue to decrease as 1/n(t), but is given by:
Thus, the curve of variant frequency versus depth predicted by the two methods is very different in this region ( Figure 6 , main paper). The Williams et al. 5 curve continually decreases with increasing depth with an asymptotic limit of zero, whereas the model we propose has an asymptotic limit of kmut-eff.
In the region where kmut-eff n(t) ≈ 1, there is a transitional zone and the predictions begin to diverge. To describe the entire curve precisely, we utilize conditional expectation values for the expected number of mutant alleles simultaneously arising at particular site at a time t, when n(t) = D cells are each undergoing individual divisions, rather than utilizing an infinite sites approximation. (Note throughout our treatment and that of Williams et al. 5 , the assumption is that at a depth D we are on average sampling cells formed at time t where n(t) =D). The term conditional means we will apply the condition that at least one mutant allele has been experimentally observed at the site in question. At very low depth relative to the reciprocal of the effective mutation frequency, most sites will have no mutant alleles, a small minority will have one mutant allele, and increasingly smaller minorities will have higher integral numbers of mutant alleles, leading to a non-integral average as described above. At these low depths, if a single mutant allele is observed the number of mutant alleles cannot be zero, and one is a much more likely value than higher integral values. Thus, the infinite sites approximation, which assumes that the mutant allele number is in fact one wherever mutations are observed, is effective in this range. If the mutant allele number is one, the mutant allele fraction will be 1/n(t) as asserted by Bozic et al. 6, 7 and Williams et al. 5 .
To develop an expression that will be accurate at all depths, we start with an exact expression for the total number of mutant alleles expected to be newly formed at a particular site at time t, which is a probability weighted average of all possible integral values from 0 to n(t), where pn is the probability that there are n simultaneously formed copies of the mutant allele: We can now compute the conditional expected value of the number of mutant alleles newly formed simultaneously at a particular site given that this number is greater than or equal to one, i.e. at sites where there has been at least one mutation. We take a weighted average again of integral values of 1 or greater, not including zero. 
(Equation S13)
We note that the sum in the numerator, from 1 to n(t), is the same as the sum from zero to n(t), since the zero term is zero. Further the denominator is equal to the sum from zero to n(t) (previously noted to be 1) minus the zero term, the probability of no mutant alleles, or p0. Making these substitutions, we have:
Substituting the value of the numerator from equation S12, and the value of p0 from equation S6 (p0 and average fapparent unmutated are synonyms), we obtain:
To derive the conditional expectation of the mutant allele fraction, we divide by n (t), setting n(t) = D as before:
To evaluate this expression at depths much lower than the reciprocal of the effective mutation frequency, we expand the exponential in a Taylor's series. Taylor's theorem states that any continuous function f(x) may be expanded in the region around f(a):
where f', f'', and f''' are successive derivatives of f.
At depths much lower than the reciprocal of the effective mutation frequency, the exponent is nearly zero, and the exponential term may be approximated by a Taylor's series with f(a) = e a , a = 0, Δa = -kmut-eff D, truncated at the linear term, i.e.
Applying this approximation to equation S16, we see that at low depth the conditional expected average mutant allele frequency is equal to 1/D ≈ 1/N(t), in agreement with Williams et al. 5 .
But at high depth, where D is greater than the reciprocal of the mutation rate, the mutant allele frequency does not approach zero as in the Williams et al. 5 formulation. Rather, examining equation S16, the exponential term approaches zero, and the conditional expected average mutant allele frequency approaches kmut-eff.
Williams et al. 5 have performed a simulation and compared it successfully to their mathematical treatment. This shows that the mathematics and simulation are mutually consistent. However, the simulation utilized only 10 6 individual cells, the technical limit of such stochastic simulations, and within the range of validity of the infinite sites assumption. The model results were then "scaled up" using the same assumption, to a full-size tumor. The infinite sites assumption is, in our opinion, not applicable in that range, and therefore one cannot use it to evaluate clinically detectable tumors. The underestimate of the total burden of mutations in the tumor associated with the infinite sites assumption is given by the area between the two predicted curves of mutation frequency versus depth at high sequencing depth >> 1/kmut-eff ( Figure 6 , main paper). Although the difference in asymptotic limits in the y axis is small, equal to kmut-eff, the x-axis width of this region is three orders of magnitude greater at diagnosis (10 9 cells) than the region of validity of the infinite sites assumption (up to 10 6 cells). Moreover, as the malignancy grows and spreads, it could contain as many as 10 12 cells in the terminal phase. Thus, the area between the curves represents a quantitatively significant difference in the predicted diversity with and without the infinite sites assumption (Figure 7 , main paper).
• Consequence of the two models' divergent predictions at very high depth: a theoretical estimate of the total mutation burden within the tumor, and a calculation of the extent of drug resistance to one drug or to multiple non-cross resistant drugs due to mutation(s) within the same cell, as given in this work, requires a model which is accurate in the range kmut-eff n(t) >>1. Due to the ever-increasing number of cell divisions per cell generation as the tumor grows, the discrepancy between the two models is quantitatively significant when the problem of the total mutational burden within the tumor is considered. • Mathematical form of the predictions: although the Williams et al. 5 formulation and ours both predict linear relationships of genetic diversity as a function of sequencing depth, the measure of genetic diversity on the y axis differs. In Williams et al. 5 , the y axis is the intuitive quantity of number of unique subclones. Because this approximate treatment is accurate within the depth range of our experiments, and is intuitive, we have presented it this way in the main text. However, our more general formulation presented herein has the y axis as the natural logarithm of the unmutated fraction of bases sequenced, i.e. ln(1-x) where x is the fraction of the capture set for which a variant sequence is detected. Moreover, the presentation of Williams et al. 5 has a positive slope proportional to the effective mutation rate, whereas ours has a negative slope equal to the effective mutation rate, due to the different quantity on the y axis. • Near equivalence of the two formulations at low depth: we have given above both a qualitative argument and a mathematical argument for the near equivalence of the formulations at low depth, the latter focusing on the mutant allele frequency curve as a function of depth. We now will again show this near-equivalence at low depth, this time focusing on the curve of observed unique subclonal mutations as a function of depth. We begin with equation S7, noting that Fapparent-unmutated = 1 -x, where we use x to denote the fraction of sites within the capture set at which at least one copy of the mutation has been observed. Thus, equation S7 becomes: 
At low depth, x << 1, since variants will be detected only in a minority of the capture set loci. Thus, the higher order terms in x are negligible, and we have
) But x, the fraction of sites with a variant observed, is proportional to the number of observed unique variants, so that plugging equation S21 into equation S19, we see that the number of observed unique variants is nearly exactly proportional to the depth, at low depths, as asserted by Williams et al 5 .
In summary, our model and that of Williams et al. 5 give indistinguishable predictions at depths less than 1/kmut-eff, but differ in important ways at higher depths representing three orders of magnitude of further tumor growth before the tumor grows to the minimal size at which it can be diagnosed clinically.
Bozic et al. 6 use a stochastic model to assess neutral evolution, and derive a correction to the Williams et al. 5 formula, which is significant at low depths (10-100) representing subclones with an apparent frequency of 10 0 to 10 -2 . Bozic et al. 6 validate their approach using data in this range. Stochastic effects are more prominent with small numbers of cells, and the Bozic et al. model 6 will be more accurate in this very low depth range than either the Williams et al. 5 approach or ours. The Bozic et al 6 model gives two correction factors. The first 1/(1-δ) is equal to the b/(b-d) term which normalizes between the actual and effective mutation rates, and is present in both the current work and the Williams et al. 5 formulation. The second correction is factor of (1-(d/b) n(t)+1 ) which is significant at low n(t).
Importantly, however, the Bozic 6 treatment, like Williams et al. 5 , uses the infinite sites approximation and is thus not applicable when the tumor cell number increases beyond the reciprocal of the effective mutation rate, or at sequencing depths greater than this number. A chart of the regions of validity of the stochastic infinite sites model 6 the continuous infinite sites model 5 and the model herein is provided in Figure 5 , main paper.
We have compared our methods and work to earlier related work, particularly Williams et al. 5 and Bozic et al. 6 . Our independently developed work has striking similarities to but important differences from these earlier studies. Importantly, all three methods give the same predictions in the range of DNA sequencing depths currently explored experimentally, with the exception of very low depths, where the stochastic treatment of Bozic et al. 6 is more accurate. The other methods utilize the "infinite sites assumption" 14 , which assumes that any mutation is unique at the instant it is formed. This assumption is true as long as the product of the effective mutation rate and the number of cells comprising a cell generation is much less than one. That condition is met for all experimental work done to date, as well as the conditions of all prior simulations. However, our experimental results document a higher effective mutation rate than previously considered, of the order of 10 -6 . We then consider the "thought experiment", currently not feasible, in which every cell in the smallest diagnosable tumor mass, or 10 9 cells, is sequenced to determine the total mutation burden of such a mass. Under these conditions, the "infinite sites assumption" will be violated, since it is violated in all cell generations involving on the order of 10 6 cells or higher. Our method is unique in that it accurately quantifies the mutation burden in this situation, because it is independent of the "infinite sites assumption" (Figures 5-7 ). This allows us to make more accurate and definitive statements about drug resistance than was previously possible. We conclude that within a tumor mass of 10 9 cells, no DNA locus will be wild type in every cell unless mutations at that locus are lethal. While many authors have stated that each tumor cell is distinct (which could be achieved with diversity at a limited number of sites), and that pre-existing resistance to a single therapy is likely to be common, we can now say that pre-existing resistance to a single therapy in at least one cell from single base substitutions alone is universal and inevitable.
Discussion of assumptions and approximations of the model 5,10,16-26
We discuss the following caveats to the proposed model: (1) . The proposed model assumes that most mutations are neutral, (2) the proposed model assumes an average effective mutation frequency kmut-eff can be calculated across subclones, which may be mutating at different rates, (3) the proposed model estimates the total mutational burden of the tumor by extrapolation from the genes sequenced to the entire genome, and (4) the proposed model estimates the total mutational burden of the tumor by extrapolation from the maximum sequencing depth to a much larger number: i.e. the total number of cells in the tumor.
Assumption of neutrality.
We have observed a linear curve of the logarithm of the fraction of apparently unmutated bases as a function of sequencing depth. If selection associated with partial or complete clonal sweeps reduced or eliminated subclonal diversity, the absolute value of the slope should decrease with increased sequencing depth, resulting in upward curvature (less negative slope), contrary to observation. Moreover, this upward curvature would produce linear regressions with negative y-intercepts, again contrary to observation. Thus, there is no evidence from our experimental data for deviation from neutrality.
A variety of experimental and theoretical studies support the notion that, while certain key sites are highly selected in carcinogenesis, the majority are neutral. A recent population dynamic analysis of a large number of microscopic sectors of a hepatocellular carcinoma biopsy was found to be wholly consistent with a neutral model 16 . An analysis of mutation burden of tumors as a function of depth using the TCGA database was published which strongly supports a neutral evolutionary model for colorectal cancer 5 . Moreover, a theoretical study of driver and passenger mutations, supported by bioinformatics analysis of observed mutations, has concluded that neutral passenger mutations are more numerous 26 , and neutral Poisson models have been previously employed in the analysis of divergence between metastases and primary 18 , and in the timing and heterogeneity of resistance mutations 19 .
A comprehensive survey of nonsynonymous/synonymous mutation ratios adjusted for tissue and sitespecific mutation patterns found a maximum of 1,230 positively selected genes in cancer at the 0.05 level of significance, and when the significance threshold is adjusted to reduce the false detection rate due to a large number of statistical comparisons, the number of definitively positively selected genes reduced to 45 21 . This amounts to anywhere between 0.15% and 4% of the approximately 21,000 genes in the human genome. Even within a positively selected gene, it is likely that no more than 28% of the amino acids within the corresponding protein affect function when mutated 22 . Overall, therefore, somewhere between 0.04% and 1% of genomic bases are expected to be positively selected in cancer.
Regarding negative selection, Zhou et al. found between 16 and 326 genes affected, depending on the significance threshold, an even smaller percentage of the genome 21 . A survey of "never mutated" genes in the TCGA database, found only 5% of the genes fit into this category 23 Even in normal germline cells, no more than 11% of mutations are projected to reduce organismal fitness 24 , but the evolutionary constraints on tumor cells are expected to be far less than on multicellular organisms 25 . Further, Martincorena et al. 10 performed an extensive analysis of nonsynonymous/synonymous mutation ratios in somatic tissues, both cancerous and normal tissues. They concluded that only 0.02% to 0.5% of genes showed evidence of negative selection. They estimated that an average of only 0.5 mutations per consensus tumor genome were purified out by negative selection. Thus, only a minor fraction of diversity is expected to be removed by negative selection.
Average mutation frequency calculated across subclones mutating at different frequency. The evidence so far accumulated indicates that the most prevalent types of mutations in cancer are singlebase substitutions. This observation was probably unexpected, as these types of mutations are not associated with viral or environmental carcinogens. Viral agents usually insert or delete genomic sequences, while many chemical carcinogens act indirectly and form bulky adducts that are removed by nucleotide excision repair. Prominent in formation of single-base substitutions are errors in DNA replication resulting from misincorporation by DNA polymerases or diminutions by nucleotide-base repair. Major likely sources for single-base substitutions would be the major replicating enzymes, DNA polymerases -δ and -ε. These enzymes and interactive proteins are responsible for copying the three billion nucleotide base pairs in the human genome with only one or a very few mistakes. Errors by these enzymes or deficits in repair seem a likely cause of mutations as initially postulated in the concept of a mutator phenotype. If replicative DNA polymerases are unable to copy past bulky lesions in DNA, human cells have an armamentarium of error-prone DNA polymerases (Y -class) that can be brought to a stall to bypass the alteration in the DNA.
Data in this manuscript documents mutations in DNA polymerase genes, and, while most of these are not known to have functional consequences, it highlights the possibility that subclones may exist with differing mutations in the genomic maintenance machinery, resulting in differing rates of evolution. The mathematical treatment herein assumes that the effective mutation frequency is a population-weighted average of these different subclones and their mutation frequencies, and that this population weighted average is approximately constant at different levels of subclonal allele frequency.
We have observed a linear relationship between the logarithm of the fraction of apparently unmutated bases and sequencing depth. If serial mutator mutations progressively accumulated during tumor growth, and these subclones represented a large enough subset to alter the averages, one would expect subclones which formed later in tumor growth to have higher mutation rates and to generate more unique variants. Due to the branching nature of tumor evolution, these mutator subclones, progressively arising later, would correspond to rarer variants and the absolute value of the slope should increase with increasing depth, resulting in downward curvature (more negative slope), contrary to observation. Moreover, this downward curvature would produce linear regressions with positive y-intercepts, again contrary to observation. The data do not rule out the existence of hypermutator clones. However, there is no evidence from the data for hypermutator clones being prevalent enough to skew the averages computed by the model. A selective advantage for hypermutator clones may appear under selection pressures by therapy, which might favor subclones that can more rapidly acquire multiple resistance mutations 17 . Under those circumstances, these hypermutator clones may increase in relative prevalence or even become the dominant clone. However, the current study involves samples obtained at diagnosis, and under neutral evolution in the absence of therapy the proportion of hypermutator subclones might be expected to remain relatively constant. As long as the population weights of the different subclones are stable over time, kmuteff can be calculated as a population weighted average.
Extrapolation from the genes sequenced to the entire genome. Analyses discussed in the main article saw only minor differences in mutation frequency between the various genes sequenced. While there is known sequence variation in the mutation frequency throughout the genome, it seems most unlikely that all of the chosen genes with similar mutation frequencies were mutation hotspots. Therefore, it is more likely that they represent a reasonable approximation of an average mutation frequency.
Extrapolation from the maximum depths achieved to every cell in the tumor. The estimate of total mutational burden of the tumor provided, and the conclusions about the likelihood of an arbitrarily selected site being mutated, depend on extrapolation of the depth achieved in this study to single cell depth representing every cell in the tumor. Although this study achieved unprecedented sequencing depth, we cannot rule out the possibility that the linear curves seen in Figure S1 might begin to level off (i.e., develop upward curvature) at still greater depth.
Dependence on growth pattern and evaluation of consequences for estimation of actual and effective mutation rate in tumors 27 )
The results described above correspond to an average mutation frequency of 7.1 X 10 -7 mutations per base per effective cell division. The actual number of cell divisions and average mutation frequency per base per actual cell division cannot uniquely be determined from this analysis, as they depend on the actual cell birth and death rates, whether these are constant, and whether the growth pattern is exponential or Gompertzian. Table S4 illustrates various scenarios and the numbers of actual cell divisions and mutation rates per actual cell division, which would be consistent with the data for the given scenario.
As illustrated in row 1 of the table, if there is simple exponential growth and no cell death, actual and effective mutation frequencies and actual and effective cell division numbers are identical. The birth and death rates from row 2 were estimated from colorectal cancer clinical data 27 . As illustrated in rows 2 and 3, as the birth and death rates become more closely matched, it takes more actual cell divisions to successfully increase the cell numbers by 1, and the actual number of cell divisions increases with a compensatory decrease in the average mutation frequency per actual cell division to account for the observed results. In Gompertzian growth, the exponential growth rate exponentially decreases, reaching zero when the number of cells in the tumor reaches the carrying capacity C. At any given moment, the growth dynamics are given by the Gompertz differential equation:
where n is the number of cells in the tumor, C is the maximum carrying capacity, and g0 is the initial net growth rate. We assume in the calculations and simulations for the table that the carrying capacity is 10 10 cells, 10 cm 3 , a conservative assumption, since larger lesions are commonly seen, and that the tumor grows to 10 9 cells by the time of diagnosis.
Gompertzian growth dynamics can be implemented in several ways. In row 4, we make the assumption that birth and death rates both proportionally decrease with increasing tumor size until they both equal zero at the carrying capacity. This maintains a constant ratio of birth to death rates, and, therefore, equation 1 Methods can be integrated and equation S6 still holds. In this simplified case, Gompertzian growth dynamics is straightforward to analyze (row 4) and produces identical results to the comparable exponential case.
However, a more realistic Gompertzian implementation may be a constant death rate and the birth rate decreasing to equal it at the carrying capacity. In this case,
where the actual number of cell divisions required to produce a new cell is b/(b-d). This case was simulated by dividing the growth from a single founder cell to 10 9 cells into 30 doublings, with each doubling requiring more cell divisions, due both to the number of "effective" cell divisions needed to double the numbers, and to the increasing value of b/(b-d). The total number of cell divisions is given by: It should be noted in Equation S24 that the estimate of total cell divisions is an n-weighted sum and is dominated by the larger values of n where more actual divisions are required to create a single new cell. In contrast, as shown above by equation S4, the observed mutations from each doubling are equal in number. This is because, even though later doublings involve more cells, mutations arising in any single cell are in rarer subclones and are less likely to be observed at limited depth. These effects cancel each other out. Thus, the total observed mutations are proportional to an unweighted sum of b/(b-d) = ln(C)/[ln(C) -ln(n)].
As a result of this effect, in row 6 for example, the number of actual cell divisions increases relative to row 1 by 7.2-fold, potentially implying that the average mutation frequency per actual cell division should be 7.2-fold lower than the effective mutation frequency derived from the analysis. However, in this scenario, a large fraction of the actual mutation burden is generated later in the process of tumor growth when the tumor begins to approach 10% of the carrying capacity and, therefore, there are many actual cell divisions per effective cell division. These later mutations are present only in very rare subclones since they arise very late in tumor development, and would go largely unobserved, even at the high depths achieved in this study. Hence, the effective mutation frequency is 3-fold underestimated in this scenario, and, thus, the actual mutation frequency, while 7.2-fold lower than the true effective mutation frequency, is only 2.4-fold lower than the apparent effective mutation frequency.
At high enough depth in the scenarios of rows 5 and 6, increasing mutations should be detectable corresponding to these rare subclones, leading to downward curvature (increasing negative slope) and an apparent positive intercept of the lines in Figures S1a-e. These were not observed, either because the Gompertzian models in rows 5 and 6 are not applicable or because the depth was insufficient to demonstrate this effect. Row 5 utilizes the birth and death rates from Diaz et al. 27 , as starting values when the tumor is small. Row 6 assumes a death rate of zero and an exponentially decreasing birth rate.
The effective mutation rate per nucleotide per new cell added to the tumor is the experimental observable in this work. The actual mutation rate per nucleotide per actual cell division cannot be determined without knowledge of the proliferation history of the tumor. For a given measured effective mutation rate, the inferred underlying actual mutation rate will be lower the more closely matched cellular birth and death rates are. When cell birth and death rates are closely matched, each effective cell division, i.e. increase in cell number by one, reflects more actual cell divisions.
The actual mutation rate per nucleotide per actual cell division reflects the underlying biophysical properties of the cell's DNA repair and replication machinery, and cannot change without a change in mutagens in the environment or a change in the DNA repair or replication machinery. We assume the actual mutation rate to be constant for much of tumor growth (see assumptions and approximations of model above).
In some growth patterns, such as Gompertzian growth, the cell birth and death rates become more closely matched as the tumor grows. Given a constant actual mutation rate, the effective mutation rate will thus increase over time. However, mutations occurring later in the tumor's history are rarer and harder to detect. Thus, sequencing fewer than every cell in the tumor will, under Gompertzian growth, lead preferentially to detection of mutations from earlier timepoints in the tumor's history, prior to the increase in effective mutation rate. This will lead to an underestimate of the average effective mutation rate over time, and an underestimate of the mutational burden within the tumor. Our conclusion that no nucleotide locus is wild type in every cell will be even more definite under these circumstances.
We have observed, as predicted for exponential growth, a straight line of the curve of the natural logarithm of the unmutated fraction of sites when plotted against sequencing depth. Gompertzian growth predicts increasing slope, and therefore curvature, as the effective mutation rate continually increases. Thus, we find no evidence for Gompertzian growth as far forward as we can see in time. We cannot rule out that Gompertzian growth may occur later in tumor development; this would only further increase the mutation burden as described above.
Consequences for the mutator hypothesis 24, 28 The mutator hypothesis states that the actual mutation frequency per base per cell division in tumors is higher than the actual mutation frequency per base per cell division in normal tissues. Lynch (2010) reviews a variety of estimates of mutation frequencies in normal tissues 24 , including studies of the development of retinoblastoma in heterozygous carriers, studies of the APC gene in intestinal epithelia, studies of the HGPRT genes in cultured lymphocytes and fibroblasts, and studies of the PigA gene in cultured lymphocytes. These estimates range from 2.7 X 10 -10 to 1.5 X 10 -9 mutations per base per actual cell division. Roach et al. sequenced whole genomes of a family of four and only 70 mutations were identified between generations 28 . They estimated a human inter-generational mutation frequency of 1.1 X 10 −8 per nucleotide position per haploid genome. Assuming that by adulthood an individual gamete undergoes 100 cell generations, the mutation frequency per cell generation would be 1 X 10 −10 per nucleotide.
In contrast, the estimated mutation frequencies per single base per actual cell division in colorectal tumors in a large variety of tumor growth scenarios including Gompertzian growth are illustrated in Table S4 , ranging from 2.8 X 10 -8 to 7.1 X 10 -7 , a numerically higher range than estimated for normal tissues. This comparison would appear to generally support the mutator hypothesis. However, this conclusion cannot be definitive as the actual growth patterns of both normal tissues and tumors are still unknown.
Probability of existence of at least one tumor cell with a mutation at a given base.
Mathematical models of mutational acquisition of drug resistance in cancer have been created by many groups beginning with Goldie and Coldman 29 . Based on this framework, other modelers 30, 31 concluded that drug resistance to single agent therapy might frequently be pre-existing. Loeb et al 32 and Sottoriva et al 13 pointed out that mutational diversity leading to drug resistance would be further enhanced in the presence of a mutator phenotype, while Sottoriva and colleagues 5, 13 emphasized the point that neutral evolution would also enhance diversity.
Bozic et al 7 modeled the acquisition of drug resistance using a branching pathways approach, demonstrating in detail that single agent therapy would inevitably lead to drug resistance, that the probability of pre-existing resistance would continuously increase with tumor size, and that simultaneous combinations would outperform successive single agents if the components of the combination could be safely given at effective dosages. Beckman, Schemmann, and Yeang 17 and Yeang and Beckman 33 studied this problem in the setting where simultaneous combinations require meaningful dose reduction due to toxicity. They found that frequent adaptation with pulses of simultaneous combinations and full dose monotherapy governed by an evolutionary model and subclonal tracking greatly outperformed the application of simultaneous combinations until failure.
The above authors all discussed the likelihood that many instances of drug resistance are due to preexisting resistant subclones at diagnosis, and this idea has been validated in numerous studies where resistance mutations found at clinical relapse were detected as minority subclones at diagnosis 34 . However, these studies relied on low depth sequencing. Moreover, many of these approaches relied on the infinite sites assumption, leading to underestimates of the total mutational burden in tumors sufficiently large to be clinically detected, as discussed above. Based in the current work we conclude that preexisting resistance to single agent therapy is universal and inevitable.
The average number of cells harboring any mutation of interest will be kmut-eff N, which for a tumor of 10 9 cells means there will be on average 700 cells resistant to any single agent at diagnosis, even if there is only one mutational mode of resistance. Moreover, we can calculate the likelihood of resistance to more than one non-cross resistant therapy occurring simultaneously in the same cell, finding it is low at diagnosis but that it increases as the tumor grows, in agreement with Bozic et al 7 . However, given our highly accurate sequencing methods, and our theoretical model which is free of the infinite sites assumption and therefore applicable to clinically relevant tumor sizes, our estimates of these quantities will be more accurate and more generally applicable. These likelihoods correspond only to resistance due to mutations alone. As there are other sources of resistance (see below), we can at times see immediate resistance to non-cross resistant combinations in the clinic.
From the average value of kmut-eff of 7.1 X 10 -7 , we determine the likelihood that every cell is unmutated at any given neutral single base locus at diagnosis. We assume the tumor burden ranges from 1 cm 3 , the approximate limit of computed tomography detection, to 10 cm 3 , representing multiple or slightly larger lesions at diagnosis. Many authors assume 10 9 cells/cm 3 , but a recent study 15 suggests there could be as few as 10 8 cells/cm 3 . Thus, depending on the size of the tumor at diagnosis and their cellular density, a patient could have 10 8 -10 10 malignant cells. Assuming 10 9 cells, and applying equation S8, the probability that any given locus is unmutated at every cell in such a small lesion is 10 -308 . Thus, it is extremely unlikely that there is any nucleotide in DNA that is wild type in every cell, even at diagnosis. This result is robust. If we have overestimated the effective mutation frequency by a factor of 10, the probability of a neutral single base locus being unmutated in every cell in the lesion is 10 -31 . For the probability of a neutral single base locus being unmutated in every cell in the tumor being as high as 1%, we would have had to have overestimated the effective mutation frequency by 150-fold. The above figures become even more striking as a cancer grows from 10 9 cells at diagnosis to 10 11 -10 12 cells in the terminal phase.
It is apparent from the above discussion that any given genomic position that is capable of encoding resistance to any therapy is highly likely to be mutated in at least one tumor cell at diagnosis, unless mutation of the position confers a significant fitness disadvantage in the absence of therapy. Moreover, it is likely in most cases that multiple single base loci in the genome confer resistance; further increasing the likelihood that at least one resistant cell will be present. While the number of single base sites in the genome conferring a resistance phenotype is unknown, and likely varies depending on the therapy, a common assumpton is that there are on the order of 100 sites in the genome, mutation of which may confer resistance 19, 27 .
These considerations raise the obvious point of the need for more than one non-cross resistant component of therapy, whether given as simultaneous combinations 7 or as a complex sequence of simultaneous combinations and monotherapy pulses 17, 33 . Assuming complete non-cross resistance, and independence of acquisition of the resistance mutations, the probability Pno simultaneous resistance, of having no single cell simultaneously resistant to K non-cross resistant agents, for which each has R sites in the genome, mutation of which can cause therapy resistance, in a tumor of N cells is approximately, in analogy with equation S8: Several generalizations are evident from the table. One is that the required number of non-cross resistant agents to ensure no fully resistant cell depends heavily on both the tumor burden and the number of bases in the genome that confer neutral fitness resistance mutations. The table suggests that, in the event of a single base in the entire genome that confers resistance, 2 non-cross resistant therapies are required for low-moderately low tumor burdens (10 9 -10 10 cells), whereas 3 non-cross resistant therapies are required for higher tumor burdens in the 10 11 -10 12 range. However, if 100 neutral single base loci confer resistance to each agent, the number of required non-cross resistant agents rises to 3 and 4 in low/moderate and high tumor burdens respectively.
Yet, the challenge is even greater for a variety of reasons 3549 :
-The above does not consider other genetic mechanisms of resistance such as chromosomal rearrangements and copy number variation (CNV). CNV also increases the number of alleles available for dominant mutations, while making homozygosity more unlikely in the case of recessive mutations. -The above does not consider epigenetic changes leading to resistance.
-The above does not consider non-genetic forms of resistance, such as feedback loops hard-wired into cells. Each non-cross resistant therapy may itself consist of several individual agents designed to hit several nodes of a signalling network corresponding to only one genetic state. -The above does not account for partial effectiveness of therapy, inhomogeneous distribution of therapies into tumor tissues, or interactions of tumor cells with each other or with the host tissues.
Simulations of unique subclones observed as a function of sequencing depth in the presence and absence of selection: sensitivity for ruling out selection model.
Exact simulations for these cases were performed using deterministic models.
For the neutral evolution case, we use equation S6 above for the fraction of unmutated bases, a capture set of 10 kilobases, and kmut-actual of 2.0 X 10 -7 per nucleotide per actual cell division, which fits our data given the birth and death rates of 0.25/day and 0.18/day estimated based on experimental data 18 (line 2, Table   S4 ). The number of mutated sites is calculated from the fraction unmutated at the depths indicated in Figure 2 (main text).
In the selection case, we consider three groups of loci, i = 1, 2, 3 where i = 1 is positively selected loci, i = 2 is neutral loci, and i = 3 is negatively selected loci.
Let s equal the relative advantage of each group over its nearest inferior category. Let ri denote the fitness of group i. We assume r2 = 1, r1 = 1 + s, r3 = 1 -s in the simulation although the equations below are more general.
Let b be the common birth rate for all these cells, and let di be adjusted death rates calculated from the relative fitnesses assumed above. Further, let the age of the tumor from the formation of the founder cell to the time of biopsy be T in days, or bT in cell generations, where b is the birth rate in cell generations/day. Cells formed at time t with r > 1 are enriched, and cells with r < 1 depleted, according to:
For any of the three types of mutations, the number of detectable mutations at depth D is the time integral of the instantaneous number of detectable mutations at time t from 0 to T. As demonstrated above, the probability of detecting a neutral mutation in a particular locus from a cell formed at time t is a constant, kmut-eff D, and therefore may be taken outside of any integral over time. However, for positively and negatively selected genes, this constant is multiplied by an enrichment factor that is not constant (equation S26), and when integrated over time from 0 to T yields an average enrichment factor:
As a check on this, we can show that the limit of the enrichment factor as ri → 1, or as T → 0 is 1, as would be expected in the limit of no enrichment (expand the exponential in a Taylor series and truncate at the linear term, or apply L'Hôpital's rule directly to obtain these limits).
With this enrichment factor, and the fact that D and kmut-eff are constants, we observe that:
Let us further denote the relative prevalence of the three type of sites by • , where ∑ The simulations utilize T = 428 days representing 30 doublings from founder cell formation given the net doubling rate of 0.07 (b-d). Thirty doublings is sufficient for the single founder cell to grow to a diagnosable lesion with 10 9 cells.
For the selection coefficient s, we have utilized values from 0.04 to 0.25. Bozic et al 26 have modeled the selection coefficient based on evaluation of putative passenger and driver mutations in astrocytic glioblastoma and pancreatic adenocarcinoma sequences, and validated their conclusions by predicting the kinetics of appearance and growth of polyps in familial adenomatous polyposis in two of three datasets. They reached the conclusion that, even for APC, s is very small: 0.004. However, the key equation in their analysis is equation 2, in which s appears in a ratio with the mutation rate. They then use a mutation rate three orders of magnitude lower than what we have determined. Using our mutation rate, their equation 2 would give a value of s of nearly 4, which is in accord with the value of 2.76 more recently measured by direct observation of colonic stem cell crypt evolution using fluorescently labeled cells in genetically engineered mice 36 . Moreover, since the modeling of polyp appearance kinetics does not account for the likelihood of elimination of most nascent polyps by immune surveillance and other factors which may confound comparisons of tumor initiation kinetics with clinical observations 11 , the polyp modelling may not further determine their parameters. Williams et al 37 have examined bulk sequencing data from multiple sources, looking for deviations from neutral evolution in the curve of variant allele frequency versus total mutation burden (as a surrogate for time). They have not detected evidence of a value of s below 0.2, which they also state as their limit of sensitivity.
We varied a1 from 0.004 to 0.1 and s from 0.04 to 0.25, keeping a1 = a3 for convenience (the value of a3 does not matter as it is unlikely we have sequenced deeply enough to find mutations at negatively selected sites). For each combination of a1 and s, we varied kmut-eff and the y intercept to obtain the best fit to experimental data, plotted as ln (fapparent-unmutated) versus depth. Based on the various population genetic and experimental estimates for normal tissue discussed above, kmut-actual must be ≥ 10 -10 , and since kmut-eff ≥ kmut-actual, we also have kmut-eff ≥ 10 -10 . For both neutral and selection models, best fit absolute residuals were evaluated as a fraction of their corresponding datapoint, resulting in an average fractional absolute residual and a 95% confidence interval thereof for both the selection model and the neutral model. Selection models were considered ruled out when their average fractional absolute residual exceeded the upper 95% confidence limit of the comparable statistic for the neutral model. In Figure 4 , main text, we see that for a1 = 0.015, selection models with s ≥ 0.23 are ruled out.
We thus found, in agreement with Williams et al 37 , that we could rule out selection of s ≈ 0.2 or stronger, as optimal fit to the data required kmut-actual ≤ 10 -10 . We note 36 that values of s for strong drivers range from about 1 to 4. It is difficult to rule out selection if a1 < 0.01 as it determines the amplitude of curvature.
The ability to rule out selection models improves if we demand that the graph intersect the origin, a theoretical point corresponding to no unique subclones observed at a sequencing depth of zero. Further, if we demand that kmut-eff be that estimated from the linear model, the selection model is more easily ruled out. Figure 2 in the main text demonstrates this in that when kmut-eff is constrained to be the same as the neutral model, a selection model with a1 = 0.015 and s = 0.125 is easily ruled out by visual inspection. Figure 2 in the main text is graphed according to the more intuitive Williams et al 5 presentation, an approximation that is valid for the sequencing depths utilized in this study.
In principle, exact simulation of the selection model will in general not give a straight line, but a triphasic curve with lesser absolute slope with increasing duplex sequencing depth, resulting in curvature (upward slope with downward curvature for the Williams et al 5 formulation; downward slope with upward curvature for our approach). The initial phase at low depth (high variant fractions) is dominated by selected loci which accumulate rapidly in the majority of cells. Then a second phase follows representing the neutral loci which accumulate more slowly and at lower variant fractions, and thus become visible at higher depth. Finally, a third phase representing small numbers of negatively selected genes at still lower variant fractions may be observed. If we had modeled a continuous distribution of fitness, there would be a continuous downward curvature rather than 3 phases. However, the ability to observe all three phases, or indeed to observe curvature, depends on the parameters and the sequencing depths chosen. We can't rule out very weak selection or selection occurring at a very small fraction of loci. However, these latter two selection cases are themselves close to neutral evolution.
Fig. S1
. ln (Fapparent unmutated) versus sequencing depth for tumors 1 -5 (a -e), Table S2 . Parameters used in the core model or in the discussion. Input parameters are experimentally measured or inferred (number of cells in a tumor inferred from size). Output parameters are derived from the analysis. Several parameters not used in the model are discussed herein to clarify their relationship to the model. *Number of effective cell divisions is the net number of events resulting in a net increase in the tumor population by 1 cell. For a tumor of N cells originating from a single founder cell, the number of effective cell divisions is by definition N-1. Hence the parameter NE is directly estimable from the tumor size. **Subclonal mutations are called relative to the tumor clonal reference sequence, not the germline sequence. The tumor clonal reference sequence is presumably derived from the founder cell(s). Table S3 . Range of depths, number of independent depths sequenced, linear correlation coefficient R, square of the linear correlation coefficient (fraction of variation of data explained by linear model), estimated kmut-eff (minus the slope), y-intercept, and its two-sided 95% confidence interval based on t-test with 2 degrees of freedom for 5 colorectal tumors plotted according to equation S8. Results shown graphically in Figures S1a-e Table S4 . Effective and actual cell division numbers and mutation frequencies per base per effective or actual cell division for different growth scenarios, including varying cell birth and death rates, exponential growth, and several variations of Gompertzian growth. 1 Calculated using equations S1 and S8; 2 Birth and death rates as published 9 ; 3 Calculated using equations S1 and S8. 4 Simulated using equations S1, S8, S23, and S24, assuming the carrying capacity (defined below) is 10 10 cells and the tumor is sampled at a size of 10 9 . 5 In the scenarios in the bottom two rows, the effective mutation frequency is an apparent effective mutation frequency. The true effective mutation frequency is approximately three fold higher as determined by the simulation. .20 X 10 9 10 9 2.9 X 10 -7 7.1 X 10 - 7   Table S5 . Probability Pno simultaneous cross resistance that no cell in a cancer of N total cells will be resistant to all of K non-cross resistant therapies, where in each case there are R neutral single bases in the genome, mutation of which confers resistance.
Parameter

Model
Number of cells (N)
Number of neutral single base resistance loci (R)
Number of noncross resistant therapies (K)
Probability that no cell in the tumor will be resistant to all therapies (Pno simultaneous cross-resistance) 10 9 1 2 0.999 10 9 100 2 6.5 X 10 -3 10 9 100 3 > 0.999 10 10 Table S6 . Range and p-values for Tukey HSD ad hoc test based on anova for data in Figure 3 , main text. GBM signatures are significantly different from those of CRC tumor or surrounding normal tissue. Regarding the comparison of CRC and surrounding normal, the uncorrected p value suggests a significant difference, but corrected for the multiple statistical comparison the p value is no longer significant.
Comparison
Mean
Diff. Lower Upper p value
